The hypermethylated in cancer 1/sirtuin 1 (HIC1/SIRT1) axis plays an important role in regulating the nucleotide excision repair pathway, which is the main oxaliplatin-induced damage-repair system. On the basis of prior evidence that the variable number of tandem repeat (VNTR) sequence located near the promoter lesion of HIC1 is associated with HIC1 gene expression, the authors tested the hypothesis that this VNTR is associated with clinical outcome in patients with metastatic colorectal cancer who receive oxaliplatin-based chemotherapy. METHODS: Four independent cohorts were tested. Patients who received oxaliplatin-based chemotherapy served as the training cohort (n 5 218), and those who received treatment without oxaliplatin served as the control cohort (n 5 215). Two cohorts of patients who received oxaliplatin-based chemotherapy were used for validation studies (n 5 176 and n 5 73). The VNTR sequence near HIC1 was analyzed by polymerase chain reaction analysis and gel electrophoresis and was tested for associations with the response rate, progression-free survival, and overall survival. RESULTS: In the training cohort, patients who harbored at least 5 tandem repeats (TRs) in both alleles had a significantly shorter PFS compared with those who had fewer than 4 TRs in at least 1 allele (9.5 vs 11.6 months; hazard ratio, 1.93; P 5 .012), and these findings remained statistically significant after multivariate analysis (hazard ratio, 2.00; 95% confidence interval, 1.13-3.54; P 5 .018). This preliminary association was confirmed in the validation cohort, and patients who had at least 5 TRs in both alleles had a worse PFS compared with the other cohort (7.9 vs 9.8 months; hazard ratio, 1.85; P 5 .044). CONCLUSIONS: The current findings suggest that the VNTR sequence near HIC1 could be a predictive marker for oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Cancer 2017;123:4506-14.
INTRODUCTION
Acquired resistance to chemotherapy and molecularly targeted therapies used to treat human cancers is mediated by molecular alterations. Thus, a better understanding of these alterations could lead to the discovery and identification of potential biomarkers to predict treatment responses as well a reduction in acquired resistance to such therapies.
Oxaliplatin is a third-generation platinum drug that is used as a chemotherapy backbone to treat patients with metastatic colorectal cancer (mCRC) in combination with infused 5-fluorouracil/leucovorin (FOLFOX), capecitabine (CapeOX), and infused 5-fluorouracil/leucovorin plus irinotecan (FOLFOXIRI). 1 The antitumor effect of oxaliplatin is considered to be the disruption of DNA replication and transcription, primarily by cross-linking the same strand of DNA. 2 Oxaliplatin-induced DNA damage is primarily repaired by the nucleotide excision repair (NER) pathway, and activated NER may contribute to oxaliplatin resistance. 3 Therefore, genes involved in the NER pathway, such as ERCC1 (excision repair cross-complementation group 1), have been extensively studied over the past decade as predictive markers for both oxaliplatin efficacy and resistance. [4] [5] [6] However, no predictive markers for oxaliplatin have been prospectively validated.
The hypermethylated in cancer 1/sirtuin 1 (HIC1/ SIRT1) axis plays an important role in the regulation of DNA repair pathways. 7 SIRT1 is a deacetylase that regulates several types of substrates or proteins to maintain genomic instability. Among the targets of SIRT1, xeroderma pigmentosum complementation group A (XPA), which is involved in the NER pathway, is deacetylated by SIRT1; this modification leads to the promotion of the NER pathway 8 ( Fig. 1 ). HIC1, a sequence-specific transcriptional repressor, directly binds to the SIRT1 promoter and suppresses SIRT1 transcription. 9 Thus, the inactivation of HIC1 results in the upregulation of SIRT1 expression and activates the NER pathway, which may contribute to oxaliplatin resistance.
Given prior evidence that the variable number of tandem repeat (VNTR) sequence located near the HIC1 promoter, denoted as D17S5, is associated with HIC1 gene expression (Supporting Fig. 1 ; see online supporting information), we hypothesized that the VNTR near HIC1 may cause interindividual differences in clinical outcome in patients with mCRC who receive oxaliplatin-based chemotherapy. This study presents the potential value of the VNTR sequence near HIC1 as a polymorphic genetic marker in predicting oxaliplatin efficacy in different patient cohorts.
MATERIALS AND METHODS

Patients and Samples
This study consists of 4 independent cohorts: a control cohort, a training cohort, and 2 validation cohorts. Patients in each cohort are individuals with mCRC who were enrolled in clinical trials and received chemotherapy with or without oxaliplatin ( Table 1) . Of the patients enrolled in the randomized phase 3 Combination Chemotherapy and Bevacizumab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer (TRIBE) study, 10 those who received oxaliplatin-based chemotherapy (FOLFOXIRI 1 bevacizumab) served as the training set (TRIBE-B cohort; n 5 218), and those who received treatment without oxaliplatin (FOLFIRI 1 bevacizumab) served as the control set (TRIBE-A cohort; n 5 215). Two cohorts of patients receiving oxaliplatinbased chemotherapy were used for validation studies (the Maintenance Bevacizumab Only or Bevacizumab Plus Metronomic Chemotherapy in Advanced Colorectal Cancer [MOMA] cohort; n 5 176; USA cohort, n 5 73). All patients provided informed consent before entering the randomized trials along with information regarding the use of their tumor tissue to explore relevant molecular parameters. This study was conducted in accordance with the Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK). The tissue analysis was approved by the University of Southern California Institutional Review Board of Medical Sciences and was conducted at the University of Southern California/Norris Comprehensive Cancer Center in accordance with the Declaration of Helsinki and Good Clinical Practice Guidelines. 
Genotyping of the VNTR Near HIC1
Tandem repeats (TRs) at the D17S5 loci are positioned approximately 1000 base pairs (bp) upstream of the HIC1 transcription start site, and a 70-bp-long sequence is tandemly repeated from once to greater than 10 times.
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Genomic DNA was extracted from the blood using the QIAamp DNAeasy Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. To determine the genotypes for TR length, a DNA fragment containing the TR region was amplified by polymerase chain reaction (PCR) using a forward primer (5 0 -GTTGGGAG CGGGGAAATGCA-3 0 ) and a reverse primer (5 0 -TGCATTGCTAACCTGCCCCA-3 0 ). The PCR protocol is consisted of: 1 cycle for 5 minutes at 958C; 30 cycles for 30 seconds at 958C, 30 seconds at 608C, and 90 seconds at 728C; and 1 cycle for 7 minutes at 728C. PCR products were separated on 1.2% agarose gels containing biotin and were detected by ultraviolet fluorescence (Fig.  2) . Investigators involved in VNTR analyses were blinded to patient clinical data.
Statistical Analysis
To explore the predictive value of the VNTR sequence near HIC1 for oxaliplatin-based chemotherapy, the primary outcome measure was defined as progression-free survival (PFS), which was calculated from the start date of first-line chemotherapy until the first observation of disease progression or death. If progression or death was not observed, then PFS was the day of the last computed tomography scan. We also evaluated the association with response rate (RR) and overall survival (OS), which are defined as the percentage of patients experiencing complete responses and partial responses, according to Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, and the period from the start date of therapy to the date of death or of last contact if the patient remained alive, respectively. Differences in baseline patient characteristics between the 4 cohorts were examined using the Fisher exact test or the Kruskal-Wallis test, as appropriate. The power to detect an association between a VNTR in the recessive model and PFS was 80% when the minimum hazard ratio (HR) varied from 1.84 to 3.19 in 20% to 40% of patients with 2 copies of the minor allele using a 2-sided log-rank test at a significance level of .05 in the training cohort (n 5 218; 155 PFS events). The power was greater than 70% and 46%, respectively, using the same test to detect the same range of HRs with the same allele frequencies in the recessive model in the validation cohorts (MOMA cohort, n 5 176, 119 PFS events; USA cohort, n 5 73, 62 PFS events). The associations between polymorphisms and PFS and OS were investigated using Kaplan-Meier curves, the log-rank test, and the Fisher exact test. A Cox proportional-hazards regression model with stratification factors was fitted to re-evaluate the association between the VNTR and PFS and OS, considering imbalances in the distributions of baseline characteristics among cohorts. The baseline demographics and clinical characteristics that remained significantly associated with endpoints after the multivariate analysis (P < .1) were included in the final model. All analyses were performed with 2-sided tests at a significance level of .05 using SAS (version 9.4; SAS Institute, Cary, NC,).
RESULTS
Compared with the TRIBE-B training cohort, no differences in characteristics were observed in the TRIBE-A control and MOMA validation cohorts. The USA validation cohort was composed of younger patients ( Table 2) . The median PFS, OS, and follow-up was 9.7, 25.6, and 49.9 months, respectively, in the TRIBE-A cohort; 11.4, 28.6, and 48.0 months, respectively, in the TRIBE-B cohort; 9.5, 25.4, and 25.3 months, respectively, in the MOMA cohort; and 13.0, 31.1, and 43.3 months, respectively, in the USA cohort. On the basis of our previous findings that the VNTR sequence near HIC1 has different expression patterns for HIC1 between fewer than 4 TRs and at least 5 TRs (Supporting Fig. 1 ; see online supporting (7) 11 (5) (Fig. 3B) . This difference remained statistically significant after multivariate analysis (HR, 2.00; 95% CI, 1.13-3.54; P 5 .018). Conversely, these correlations were not observed in the TRIBE-A control cohort (Fig. 3A) . These data suggest that the VNTR sequence near HIC1 may be associated with oxaliplatin efficacy in patients with mCRC.
Validation Studies
In the MOMA validation cohort (S/S genotype, 81%, S/L genotype, 14%, L/L genotype, 5%), the preliminary association observed in the training cohort was confirmed. Patients who had the L/L genotype had a significantly worse PFS compared with those who had either the S/L or S/S genotype after univariate analysis (median PFS, 7.9 vs 9.8 months; HR, 2.13; P 5 .044) (Fig. 3C ), yet this correlation was not statistically significant after multivariate analysis (HR, 1.92; 95% CI, 0.87-4.24; P 5 .105). Furthermore, to exclude the impact of irinotecan on clinical outcomes, we examined the association of the VNTR sequence in patients who received treatment with FOLFOX or CapeOx backbone in the USA cohort. There was no evidence of an association with PFS between patients with the L/L genotype and those with the S/L or S/S genotype (Fig. 3D) . However, patients who had more than 5 TRs in both alleles (n 5 4) had a borderline significant trend toward shorter PFS compared with the other cohort (n 5 69) after univariate analysis (8.1 vs 13.0 months; HR, 2.28; 95% CI, 0.80-6.47; P 5 .098) (Supporting Fig. 2 ; see online supporting information).
Subgroup Analysis
Given the previously reported biologic features of CRC, [12] [13] [14] subgroup analyses by sex, primary tumor location, and viral rat sarcoma gene (RAS) status were performed. Primary tumor locations were grouped into those on the right side (cecum, ascending colon, and transverse colon) and those on the left side (descending colon, sigmoid colon, and rectum). RAS status was divided into 2 groups: all RAS wild-type and other types. Figure 4 
DISCUSSION
Although many drug combinations have emerged as possible options as first-line chemotherapy for patients with mCRC, several controversial issues remain, including the choice of an optimal chemotherapy backbone. In the clinic, either FOLFIRI or FOLFOX (or CapeOx) is selected as the first-line chemotherapy backbone based on practical issues, patient preference, and toxicity profiles, because no substantial differences in efficacy have been demonstrated between these regimens. 15, 16 FOLFOXIRI has been proposed as a feasible option with a high antitumor activity and acceptable toxicity, 17 ,18 yet the eligibility criteria have some limitations because of the high intensity of the treatment. Therefore, biomarkers predicting drug efficacy, resistance, and/or toxicity could help with selecting the most favorable first-line chemotherapy regimen for patients with mCRC.
In the current study, we observed that the VNTR sequence near HIC1 was significantly associated with PFS in patients who received oxaliplatin-based chemotherapy, but not in those who received irinotecan-based chemotherapy, suggesting that this VNTR may be a predictive marker for oxaliplatin efficacy. TRs, which are stretches of DNA composed of 2 or more contiguous copies of the Original Article same genomic sequence, exhibit a length polymorphism that potentially could be used as a genetic marker. Although the functional role of TRs is unclear, growing evidence has revealed that certain TRs located in the 5 0 -untranslated region exert functional effects on gene expression by modulating the binding of transcription factors, the distance between promoter elements, splicing efficiency, or DNA structure. 19 We previously reported that the VNTR sequence near HIC1 was significantly associated with HIC1 expression: Once the smaller allele exceeds 4 repeats, higher levels of HIC1 expression were no longer observed, and a trend of decreasing expression was evident (Supporting Fig. 1 ; see online supporting information). In this study, we observed a clear difference in PFS between patients who had fewer than 4 TRs and those who had at least 5 TRs. Although this observation was not confirmed in the USA cohort, potentially because of the small sample size, the observation that patients who had at least 6 TRs in both alleles had a trend toward worse PFS is consistent with the inverse correlation between larger numbers of TRs and lower levels of gene expression.
Downregulation of HIC1 associated with large numbers of TRs may lead to the overexpression of SIRT1 because of transcriptional suppression by HIC1. 9 The biologic rationale between HIC1/SIRT1 expression and oxaliplatin efficacy, however, currently remains unclear. NER is a repair pathway for single-strand breaks: DNA damage induced by UV light and platinum drugs (eg, cisplatin, carboplatin, and oxaliplatin) is repaired by the NER system. [20] [21] [22] In the NER pathway, it is believed that XPA, a target of SIRT1, is the core factor responsible for platinum drug resistance, 8 because several studies have demonstrated that XPA is overexpressed in cisplatinresistant cancers. [23] [24] [25] In the multistep process of DNA repair, XPA plays a role during the damage recognition or verification phase, interacting with RPA (replication protein A) (Fig. 1) . Although the acetylated status of XPA reduces NER activity, deacetylation of XPA by SIRT1 could promote NER activity by facilitating its interaction with RPA, in turn leading to platinum drug resistance. 8 In a recent study by Asaka and colleagues, 26 a cell line that overexpressed SIRT1 exhibited higher viability after treatment with cisplatin than a control cell line. In a mouse xenograft model, tumors that overexpressed SIRT1 exhibited stronger resistance to cisplatin compared with control tumors. Taken together, these reports indicate that HIC1/SIRT1 expression levels affect NER activity through XPA modulation, resulting in interindividual differences in oxaliplatin efficacy.
In patients with mCRC, distinct molecular profiles based on sex, primary tumor site, and RAS status have been reported. [12] [13] [14] DNA repair systems may differ by primary tumor location, as represented by differences in microsatellite instability. 27 In addition, RAS status reportedly influences DNA damage responses. 28 A previous study identified a distinct ERCC1 expression profile based on primary tumor location and RAS status, suggesting the existence of regulatory mechanisms between the NER pathway, tumor location, and RAS status. 29 It is noteworthy that we observed herein a strong association between the VNTR polymorphism near HIC1 and PFS, particularly in patients who had metastatic tumors derived from the left side of the colon or with RAS wild-type tumors. However, these associations were not confirmed in the validation study, potentially because of the small numbers of patients who had the minor L/L genotype. Future studies with a larger sample size are warranted to confirm these associations and underlying biologic mechanisms.
In conclusion, this study demonstrates for the first time the potential value of the VNTR polymorphism near HIC1 as a predictive marker of outcome after oxaliplatinbased chemotherapy in patients with mCRC. If our findings are prospectively validated, then, because the TR polymorphism can be easily examined by PCR of a blood sample, the VNTR sequence near HIC1 would be a promising biomarker to individualize the use of oxaliplatin in the clinic. 
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